Search Results for:
-
Week in Washington
The FDA is taking the first steps to blaze a new approval shortcut for drugs, both small molecules and biologics, that narrowly focus on serious or life-threatening diseases in which there's an unmet needBioWorld Insight | Tuesday, January 22, 2013 -
$0.00BioWorld Reports | Thursday, January 17, 2013
-
Other News To Note
Omeros Corp., of Seattle, said its Cellular Redistribution Assay technology identified small molecules that interact with a Class B G protein-coupled receptorBioWorld Today | Thursday, January 17, 2013 -
Galapagos Acquires Cangenix, Realigns Services Business
The Cangenix unit, which has just four employees, will remain at its present base in Canterbury, but it will become part of the Harlow, UK-based Argenta organization, which focuses on small-molecule drug discovery...It can assist in a smart way (via computer modeling) the discovery and optimization of new small-molecule drugs," De Kerpel notedBio Perspectives | Wednesday, January 16, 2013 -
Galapagos Acquires Cangenix, Realigns Services Business
The Cangenix unit, which has just four employees, will remain at its present base in Canterbury, but it will become part of the Harlow, UK-based Argenta organization, which focuses on small-molecule drug discovery...It can assist in a smart way (via computer modeling) the discovery and optimization of new small-molecule drugs," De Kerpel notedBy Cormac Sheridan | BioWorld International | Wednesday, January 16, 2013 -
Other News To Note
Priaxon AG, of Munich, Germany, said it inked a deal with GlaxoSmithKline plc, of London, to research and develop small-molecule modulators of protein-protein interactionsBioWorld International | Wednesday, January 16, 2013 -
Galapagos Acquires Cangenix, Realigns Services Business
The Cangenix unit, which has just four employees, will remain at its present base in Canterbury, but it will become part of the Harlow, UK-based Argenta organization, which focuses on small-molecule drug discovery...It can assist in a smart way (via computer modeling) the discovery and optimization of new small-molecule drugs," De Kerpel notedBy Cormac Sheridan | BioWorld Today | Wednesday, January 16, 2013 -
Karolinska Lands $34M Portfolio Investment from Rosetta Capital
Another company in the KDev portfolio that has reached Phase II trials is Axelar AB, which is developing a small-molecule inhibitor of insulin-growth factor receptor, which, unlike many other small-molecule inhibitors, does not act on the related insulin receptorBy Cormac Sheridan | BioWorld Today | Tuesday, January 15, 2013 -
FDA Begins Blazing Narrow Trail for Approval Shortcut
Hoping to beef up its arsenal against drug-resistant bacteria, the FDA is taking the first steps to blaze a new approval shortcut for drugs, both small molecules and biologics, that narrowly focus on serious or life-threatening diseases in which there's an unmet needBy Mari Serebrov | BioWorld Today | Tuesday, January 15, 2013 -
Pharma Clinical & FDA Action Update: December 2012
small molecule Castration-resistant prostate cancer Treated the first patient in the Phase II ARMOR2 studyBioWorld Insight | Monday, January 14, 2013 -
American Society of Hematology: December 2012
small molecule inhibitor of the PLK1 protein Acute myeloid leukemia Phase II data showed higher rates of objective response and a trend for longer median event-free survival when given in combination with low-dose cytarabine vsBioWorld Insight | Monday, January 14, 2013 -
New Apoptosis-Targeting Drug Gets B Cells, Spares Platelets
Highly selective small molecules are invaluable tools for studying and unlocking disease biology," he saidBy Anette Breindl | BioWorld Today | Friday, January 11, 2013 -
Improving Economic Outlook Bodes Well for Biotech in 2013
The small-molecule phosphodiesterase 4 inhibitor hit primary and major secondary endpoints, with improved safety and tolerability over previous psoriasis studiesBio Perspectives | Thursday, January 10, 2013 -
BIND, Amgen Ink $180.5M Nanomedicine Partnership
Unlike small-molecule targeted drugs, which interfere with the action of a specific protein to create a therapeutic effect, Accurins bind to a specific surface protein to concentrate the drug at the sites where it is neededBy Catherine Shaffer | BioWorld Today | Wednesday, January 9, 2013 -
Heptares' GPCR Platform Lands Cubist Collaboration
That forms the basis for using fragment-based approaches to discover new small-molecule leadsBy Nuala Moran | BioWorld International | Wednesday, January 9, 2013 -
Swiss Kareus Therapeutics Aims Its KU-046 at Alzheimer's
Those have been identified by a "network pharmacology" approach, based on identifying several points of intervention in disease networks. (See BioWorld International, Feb. 15, 2012.) Several other small-molecule and biologic-based approaches to targeting Abeta production have foundered in recent years for reasons that are not yet fully understood, but which may be linked to patients' disease statusBy Cormac Sheridan | BioWorld International | Wednesday, January 9, 2013 -
Other News To Note
Priaxon AG, of Munich, Germany, said it inked a deal with GlaxoSmithKline plc, of London, to research and develop small-molecule modulators of protein-protein interactionsBioWorld Today | Wednesday, January 9, 2013 -
Heptares' GPCR Platform Lands Cubist Collaboration
That forms the basis for using fragment-based approaches to discover new small-molecule leadsBy Nuala Moran | BioWorld Today | Tuesday, January 8, 2013 -
Clinic Roundup
EPI-743 is a small-molecule cofactor for NADPH quinone oxidase 1...ETC-1002 is a once-daily, small-molecule therapy that has been shown to be liver-selective for activation of AMP kinase and inhibition of ATP citrate lyaseBioWorld Today | Tuesday, January 8, 2013 -
Other News To Note
The small-molecule chemotherapeutic received orphan drug designation in the U.SBioWorld Today | Tuesday, January 8, 2013
Category
Current Filters
- xsmall molecule
Related Keywords
Categories
- x BioWorld Today (4781)
- x BioWorld Insight (904)
- x BioWorld International (857)
- x State of the Industry Report (117)
- x BioWorld Genomics Review (112)
- x Bio Perspectives (103)
- x BioWorld Snapshots (35)
- x Top 25 Drug Report (19)
- x Biotech Innovations (19)
- x Market-Leading Biotech Drugs (6)
- x RNAi Report (3)
- x Featured (1)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.
